REGENXBIO (NASDAQ:RGNX - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26, Zacks reports. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million.
REGENXBIO Stock Up 5.3 %
Shares of RGNX stock traded up $0.35 during trading on Friday, hitting $6.90. The company had a trading volume of 850,935 shares, compared to its average volume of 928,273. The stock's 50-day moving average is $7.34 and its two-hundred day moving average is $9.08. The stock has a market capitalization of $341.86 million, a price-to-earnings ratio of -1.37 and a beta of 1.35. REGENXBIO has a 52 week low of $5.62 and a 52 week high of $23.14.
Analyst Ratings Changes
RGNX has been the topic of a number of research analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of REGENXBIO in a research report on Wednesday, January 15th. Morgan Stanley increased their price target on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday. Chardan Capital restated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Friday. Finally, StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $34.13.
Get Our Latest Analysis on REGENXBIO
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Recommended Stories
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
